Thromboembolic prophylaxis in total hip replacement: A comparison between the low molecular weight heparinoid Lomoparan and heparindihydroergotamine

Leyvraz, P. F.; Bachmann, Fédor; Bohnet, Jean; Breyer, H.-G.; Estoppey, Daniel; Haas, S.; Hochreiter, Josef; Jakubek, H.; Mair, Johannes; Sorensen, R.; Stiekema, J. C. J.

doi:10.1002/bjs.1800790919

Cited by 34 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients who have had major hip or knee surgery low molecular weight heparins were significantly more effective than unfractionated heparin (5000 U subcutaneously two or three times a day) 17 18. Low molecular weight heparins were also more effective than adjusted dose unfractionated heparin,19 oral anticoagulants,20 21 dextran,22 23 and aspirin in such patients.…”

Section: Hospital Patients At High Riskmentioning

confidence: 96%

Fortnightly review: Prophylaxis of venous thromboembolism

Verstraete¹

1997

BMJ

View full text Add to dashboard Cite

Section: Hospital Patients At High Riskmentioning

confidence: 96%

Fortnightly review: Prophylaxis of venous thromboembolism

Verstraete¹

1997

BMJ

View full text Add to dashboard Cite

“…[24] The only study that directly compares low dose unfractionated heparin in combination with dihydroergotamine mesylate and danaparoid sodium showed that both regimens provided a similar degree of tolerability, as determined by blood losses and bleeding complications. [17] …”

Section: Bleeding Complicationsmentioning

confidence: 97%

A Comparative Review of the Adverse Effect Profiles of Heparins and Heparinoids

Borris

1995

Drug Safety

View full text Add to dashboard Cite

On the basis of the results of the 11 studies reviewed, thromboprophylaxis with unfractionated heparin, low molecular weight (LMW) heparin or a heparinoid (danaparoid sodium; Org 10172) in patients undergoing total hip replacement did not show any important clinical differences with respect to the tolerability profiles of the different compounds. However, as a result of the great variability in the presentation and evaluation of blood losses and bleeding complications in these studies, it is mandatory to perform a direct comparison of the different compounds in question in a double-blind, prospective clinical study.

show abstract

“…A newly synthetized heparinoid, ORG 10172 (lomoparan), has proven to be beneficial in recent trials (11,36). However, data are still preliminary.…”

Section: Effective Measuresmentioning

confidence: 98%

State-of-the-Art Review : Prevention of Venous Thromboembolism in Major Orthopedic Surgery

Prandoni

Goldhaber

Piccioli

et al. 1996

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Venous thromboembolism continues to be a major source of morbidity and mortality in both elective and traumatic orthopedic surgery. Prevention of this complication has received much attention in the orthopedic literature in recent years. We reviewed the relative efficacy and safety of various agents in the prophylaxis of venous thromboembolism arising after major orthopedic surgery. In patients undergoing total hip replacement, low-molecular-weight heparin in fixed doses, adjusted doses of warfarin, and unfractionated heparin in adjusted doses are the most effective prophylactic agents and are highly recommended for routine use. Low-molecularweight heparin or warfarin should be used in patients with hip fractures. Low-molecular-weight heparin, warfarin, or intermittent pneumatic compression should be used in patients undergoing major knee surgery. A number of questions still remain unanswered. In particular, further studies are needed to establish the optimal duration of prophylaxis.

show abstract

Thromboembolic prophylaxis in total hip replacement: A comparison between the low molecular weight heparinoid Lomoparan and heparindihydroergotamine

Cited by 34 publications

References 22 publications

Fortnightly review: Prophylaxis of venous thromboembolism

Fortnightly review: Prophylaxis of venous thromboembolism

A Comparative Review of the Adverse Effect Profiles of Heparins and Heparinoids

State-of-the-Art Review : Prevention of Venous Thromboembolism in Major Orthopedic Surgery

Contact Info

Product

Resources

About